To identify compounds that possess anti-infective and/or antimicrobial activity and/or increase bacterial susceptibility to standard antibiotics at the pathogen-mucosal epithelium interface; using well-defined in-vitro models; to test the potency of selected compounds to manage bacterial respiratory and intestinal infections in mice and in ex-vivo human mucosal models; assess fermentation of NDOs by the local microbiota; test airway application to treat respiratory infections and evaluate off-target effects; exercise compounds in models to study biofilm formation in-vitro and on implants (in-vitro and in-vivo).

Acting consortium members

Scroll to Top